Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase 1 Supported by USPHS Grant PO1-CA-47179. J. R. B. is an American Cancer Society Professor of Medicine and Pharmacology. 1

WeiWei Li and Joseph R. Bertino
WeiWei Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph R. Bertino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Fas and Fas-L expression. 100 μg of cellular extract was used for Western blotting analysis as described in “Materials and Methods.” Lane 1: SaOs-2; Lane 2: HT-1080; Lane 3: HS-16; Lane 4: HS-30; Lane 5: HS-42; Lane 6: A204; and Lane 7: M9110.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Effect of CH-11 antibody on cytotoxicity-induced by anticancer drugs. Cells were exposed to anticancer drugs at different concentrations for 3 days or pretreated with CH-11 (6 ng/ml) for 1 h followed by anticancer drugs for 3 days. Cytotoxicity of drugs was determined using the SRB assay. A, HT-1080; B, HS-16; and C, WI-38. (○), MTX; (•), MTX + CH-11; (▵), DOX; (▴), DOX + CH-11; (□), paclitaxel; and (▪), paclitaxel + CH-11.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Effect of CH-11 on induction of cell death by DOX and paclitaxel in HT-1080 cells. Cells were pretreated with CH-11 (6 ng/ml) for 1 h followed by DOX (0.5 μm) or paclitaxel (0.1 μm) for 24 h. Subdiploid cells were measured by FACS analysis as described in “Materials and Methods.” (□), untreated control; ([cjs2106]), CH-11; ([cjs2113]), DOX; (▪), DOX + CH-11; ([cjs2088]), paclitaxel; and ([cjs2110]), paclitaxel + CH-11. The figure is the representative of two similar experiments.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effect of CH-11 antibody on the expression of caspase-8 and caspase-9 and cytochrome c and activation of caspase-8. HT-1080 cells were treated with CH-11(6 ng/ml) or pretreated with SB203580 (10 μm) or z-IETD (20 μm), respectively, for 16 h followed by CH-11. Whole cell extracts (for caspase-8 and caspase-9) or cytosolic extracts (for cytochrome c) were prepared and used for Western blotting analysis. For caspase-8 activation assay, cells were lysed in hypotonic buffer as described in “ Materials and Methods.” A, expression of caspase-8 and caspase-9 and cytochrome c. Lane 1: untreated control; Lane 2: CH-11, 4 h; Lane 3: CH-11, 8 h; Lane 4: CH-11, 24 h; Lane 5: IETD(Ome)-fmk + CH-11, 8 h; Lane 6: IETD(Ome)-fmk + CH-11, 24 h; Lane 7: SB203580 + CH-11, 8 h; and Lane 8: SB203580 + CH-11, 24 h. B, activation of caspase-8. (○), untreated control; (•), CH-11, 1 h; (▵), CH-11, 4 h; (▿), CH-11, 8 h; and (▾), CH-11, 24 h.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Effect of CH-11 on cell cycle distribution in response to anticancer drugs in HT-1080 cells. A, cells were incubated with CH-11 (6 ng/ml) for 24 or 48 h. B, cells were exposed to DOX (20 nm) or paclitaxel (2 nm) or to CH-11 (6 ng/ml) for 1 h followed by DOX (20 nm) or paclitaxel (2 nm) for 24 h. Cells were then harvested and subjected to FACS analysis.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Activation of MAPKs by CH-11 and anticancer drugs and the effect of SB203580 on CH-11-induced activation of MAPKs and cytotoxicity of CH-11 plus anticancer drugs. A, activation of MAPKs by CH-11 and anticancer drugs. HT-1080 cells were exposed to CH-11(6 ng/ml), MTX (200 nm), DOX (20 nm), or paclitaxel (2 nm) at the indicated times, whole cell extracts were prepared for Western blotting analysis. Lane 1: untreated control; Lane 2: CH-11, 30 min; Lane 3: CH-11, 1 h; Lane 4: CH-11, 4 h; Lane 5: MTX, 1 h; Lane 6: DOX, 1 h; and Lane 7: paclitaxel, 1 h. B, the effect of SB203580 on CH-11-induced activation of MAPKs. HT-1080 cells were pretreated with SB203580 (10 μm) for 16 h and followed by CH-11(6 ng/ml) for an additional 4 h. Whole cell extracts were prepared for Western blotting analysis. Lane 1: untreated control; Lane 2: CH-11 alone; and Lane 3: CH-11 + SB203580. C and D, SB203580 inhibits the enhanced effect of CH-11 combined with anticancer drugs. Cells were pretreated with SB203580 (10 μm) or IETD(Ome)-fmk (20 μm) for 16 h then treated with CH-11 (6 ng/ml) for 1 h followed by MTX or DOX or paclitaxel for 3 days. Cell killing was determined using a SRB assay. (□), drug alone; ([cjs2113]), drug + CH-11; (), drug + CH-11 and SB203580; (▪), drug + CH-11 and IETD(Ome)-fmk; and ([cjs2106]), CH-11 alone. Drug concentration used in HT-1080 cells. (C): MTX, 200 nm; DOX, 20 nm; paclitaxel, 2 nm; and in HS-16 cells. (D): MTX, 500 nm; DOX, 100 nm; and paclitaxel, 10 nm.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (14)
December 2002
Volume 1, Issue 14
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase 1 Supported by USPHS Grant PO1-CA-47179. J. R. B. is an American Cancer Society Professor of Medicine and Pharmacology. 1
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase 1 Supported by USPHS Grant PO1-CA-47179. J. R. B. is an American Cancer Society Professor of Medicine and Pharmacology. 1
WeiWei Li and Joseph R. Bertino
Mol Cancer Ther December 1 2002 (1) (14) 1343-1348;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase 1 Supported by USPHS Grant PO1-CA-47179. J. R. B. is an American Cancer Society Professor of Medicine and Pharmacology. 1
WeiWei Li and Joseph R. Bertino
Mol Cancer Ther December 1 2002 (1) (14) 1343-1348;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement